After 5 years on the US Food and Drug Administration (FDA) Drug Shortage list, Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL is once again available in the United States, according to drugmaker Harrow. This preservative-free synthetic corticosteroid is FDA approved for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids. It has been unavailable in the US for more than 2 years.

The relaunch of Triesence follows a global collaboration to reinvent the complex manufacturing and analytical testing process for the drug and to rebuild the supply chain, Harrow chief executive officer Mark L. Baum said in a press release. The product can be ordered through major pharmaceutical specialty distributors, including Besse Medical/Cencora, McKesson Medical-Surgical, and Cardinal Health. Initial supplies of TRIESENCE will be listed under both NDC 00078-0897-78 and NDC 82667-800-01. Triesence has a dedicated HCPCS J code, J3300, for use when billing.

“The relaunch of Triesence brings much-needed relief for both eyecare professionals and their patients,” says Rishi Singh, MD, an ophthalmologist and vitreoretinal surgeon of Cleveland Clinic Florida. “During its absence, many were forced to adapt with less ideal, off-label solutions [that] posed potential risks. Now that Triesence is back, we can confidently provide safer, more effective treatment, improving surgical outcomes and patient care.”